AdPC |
prostate adenocarcinoma |
NEPC |
neuroendocrine prostate cancer |
SRRM4 |
serine/arginine repetitive matrix 4 (also known as nSR100) |
SOX2 |
sex determining region Y-box 2 |
CRPC |
castration-resistant prostate cancer |
AR |
androgen receptor |
CRPC-Ad |
castration-resistant prostate adenocarcinoma |
t-NEPC |
treatment-induced neuroendocrine prostate cancer |
TP53 |
tumor protein p53 |
RB1 |
retinoblastoma transcriptional corepressor 1 |
PTEN |
phosphatase and tensin homolog |
NE |
neuroendocrine |
SC |
stem cell |
REST |
RE1 silencing transcription factor |
EZH2 |
enhancer of zeste 2 polycomb repressive complex 2 |
LnNE |
SRRM4-transduced LNCaP cell-derived neuroendocrine prostate cancer model |
PSA |
prostate-specific antigen |
VPC |
Vancouver Prostate Centre |
RISH |
RNA in situ hybridization |
IHC |
immunohistochemistry |
E-Cad |
E-cadherin |
SYP |
synaptophysin |
BrdU |
bromodeoxyuridine |
Doce |
docetaxel |
CPT |
camptothecin |
GSEA |
gene set enrichment analysis |
PDX |
patient-derived xenograft |
GEMM |
genetically engineered mouse model |
GEO |
gene expression omnibus |
WT |
wild-type |
SKO |
single knock-out |
DKO |
double knock-out |
TKO |
triple knock-out |
LE |
luminal epithelial |
c-PARP |
cleaved poly(ADP-ribose) polymerase |
GO |
gene ontology |
DuNE |
SRRM4-transduced DU145 cell-derived neuroendocrine prostate cancer model |